– USA, MA – Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that Roger Tung, Ph.D. has been appointed to its Board of Directors. Dr. Tung is the scientific co-founder of Concert Pharmaceuticals, where he serves as President and Chief Executive Officer. Prior to Concert, Dr. Tung was a founding scientist at Vertex, a pharmaceutical company. Dr. Tung has more than 30 years of experience in the global pharmaceutical and biotechnology industries.
“I am delighted that Roger is joining our Board of Directors,” said Dr. William McVicar, Flex Pharma President and CEO. “Roger’s scientific approach to the discovery and development of new drugs is complemented by his work as the CEO and board member of a publicly traded biopharmaceutical company. He will be a valuable addition to our Board.”
“As a member of the Scientific Advisory Board over the past three years, I have been excited about the potential of Flex Pharma’s innovative platform of chemical neurostimulation to treat cramps and spasticity in several disease settings,” commented Dr. Tung. “Now, as a Board member, I look forward to contributing on a broader level as the company approaches a number of meaningful data readouts over the next year.”
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The Company’s lead candidate, FLX-787, is being developed under Fast Track designation for the treatment of severe muscle cramps associated with ALS. Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Christoph Westphal, M.D., Ph.D.
For more information : http://www.flex-pharma.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.